OS Therapies Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by OS Therapies Inc. (OSTX) on August 25, 2025. The report details the termination of a material definitive agreement with Square Gate Capital Master Fund, LLC – Series 3.
Key Financial Metrics
The filing does not contain standard financial performance metrics such as revenue, profit, cash flow, or margins. The only financial data disclosed relates to the terminated agreement:
- Agreement Capacity: The terminated Equity Purchase Agreement (ELOC) allowed for the sale of up to $15.0 million of common stock.
- Outstanding Obligations: At the time of termination, there were no outstanding borrowings, advance notices, or shares to be issued.
- Termination Costs: No termination fees or other payments were due by either party.
Material Changes
The primary material change is the termination of the ELOC Purchase Agreement dated October 31, 2024. The termination notice was delivered on August 25, 2025, and became effective on August 26, 2025. This action removes the Company's ability to access up to $15.0 million in capital through this specific facility, though no capital had been drawn down.
Outlook, Risks, and Management Commentary
Management announced the termination via a press release issued on August 25, 2025. The filing indicates the termination was executed pursuant to Section 10.6 of the agreement. No specific guidance, future outlook, or new risk factors were disclosed in this report beyond the cessation of the equity line of credit.
Key Facts for Investor Verification
- Verify the Company's current liquidity position and alternative capital sources following the termination of the $15.0 million ELOC.
- Confirm the effective date of termination (August 26, 2025) and ensure no hidden liabilities or fees were incurred.
- Review the press release (Exhibit 99.1) for additional context on the strategic rationale for terminating the agreement.